TEVA // Teva Pharmaceutical Industries Limited

DES <GO> NYSE CIK 0000818686 ↗

Health Care • Biotechnology: Pharmaceutical Preparations

$41.47 ▲ +1.50 (+3.75%)

MKT CAP: $48.32B • VOL: 5.23M

52W L $20 52W H $43

ALTMAN Z

1.02 RISK

PIOTROSKI

8 / 9

TEVA // ROARABLE RATING & 5-PILLAR RQD CONFIDENCE 02:00 EST DETERMINISTIC ENGINE

▼ DOWNGRADE // C (RQD 62) -> C- (RQD 61) AS OF 2026-11-01

ROARABLE C-

RQD CONFIDENCE

61 / 100 -1D

5 X 20-PT QUANT PILLARS

E 0 D 35 C 59 B 70 A 86+

Roarable Hold — Cautious Neutral

01 MASSIVE / SEC XBRL

Forensic Fundamentals

[LOCKED] FLAGGED

UNLOCK BELOW TO REVEAL

02 OPRA GEX + SEC 13F

Whale & Options Flow

10 / 20

NEUTRAL

NET GEX +0% • CALL SWEEP 52% • P/C 0.56

03 SEC FORM 4 (90D)

Insider Conviction

[LOCKED] FLAGGED

UNLOCK BELOW TO REVEAL

04 FRED 90D r-MATRIX

Macro Regime Fit

14 / 20

SOLID

TAILWIND • r(10Y)=+0.00 (+23bp) • r(OAS)=+0.00

05 10-K REDLINE AUDIT

Forensic 10-K Risk

16 / 20

STRONG

20 BASE - 4 DEDUCT • 0 CRIT / 0 MED • STABLE

ALERT

Why did TEVA's Forensic Fundamentals & Insider Conviction sub-score just flash a warning? Enter your email to unlock the full 5-Pillar Rating Breakdown + get instant alerts whenever TEVA is Upgraded or Downgraded.

SIG <GO> CROSS-FEED TRIANGULATION // PROPRIETARY ANOMALY ENGINE (1 ACTIVE ON TEVA)

STAGE 2 DETERMINISTIC Z-SCORE + STAGE 3 GEEK DESK BRIEF ALL MARKET ANOMALIES <SIG>

▼ BEARISH // F-RATED EARNINGS MIRAGE // ACCRUAL WATCHSIFTER 02 // ACCRUAL & RECEIVABLES FORENSICS

SEVERITY: 84/100 Z-SCORE: +2.55σ

TEVA Accounting Gap: Net Income (+186%) Outpaced OCF (+32.2%) With +8% Working-Capital Build

CASH CONVERSION GAP

+153.8% (NI vs OCF)

RECEIVABLES / WC BLOAT

+8.0% VS REV

60D C-SUITE FORM 4 SALES

0 OPEN-MKT DUMPS

[GEEK DESK FORENSIC NOTE // SEC XBRL × FORM 4 CROSS-CHECK]

SEC EDGAR XBRL CompanyFacts10-K/10-Q Working Capital ScheduleSEC Form 4 Executive Sales

SEC EDGAR XBRL triangulation on Teva Pharmaceutical Industries Limited (TEVA) exposes a +153.8% Cash Conversion Gap as YoY Net Income growth (+186.0%) diverged from Operating Cash Flow growth (+32.2%). Non-cash current assets and receivables expanded +8.0% relative to top-line revenue growth. Monitor upcoming 10-Q cash realization closely for accrual mean-reversion.

TEVA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +20.02%📐 HORIZONTAL RANGE

2026-10-30O $41.17H $42.59L $41.17C $42.09VOL 7.36M

RES: $43.46SUP: $23.90SMA50: $39.08SMA200: $34.58

TEVA // INSTITUTIONAL BULL VS. BEAR FORENSIC DEBATE

NEUTRAL / PAIR TRADE CONVICTION: 47/100

BEAR 0

100 BULL

Teva Pharmaceutical Industries Limited (TEVA) exhibits 51.8% gross margins and 9.4% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 20.8x enterprise multiple and 6.9% implied options volatility.

▲ INSTITUTIONAL BULL THESIS (LONG)

01. Operating Leverage & Capital Efficiency Moat

Sustained 51.8% gross profitability converts into 12.5% operating margin and 9.4% ROIC, outpacing sector cost of capital.

ROIC: 9.4% // GM: 51.8%

02. Top-Line Expansion & Cash Conversion

YoY revenue trajectory of +4.3% paired with 1.81% free cash flow yield supports self-funded R&D and capital return.

REV YOY: +4.3% // FCF YLD: 1.81%

03. Balance Sheet Solvency & Forensic Quality

Altman Z-Score of 1.02 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.

ALTMAN Z: 1.02 // F-SCORE: 8/9

▼ INSTITUTIONAL BEAR THESIS (SHORT / RISK)

01. Multiple Compression & Duration Sensitivity

Trading at 34.3x trailing P/E (31.9x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.

P/E: 34.3x // EV/EBITDA: 20.8x

02. Options Skew & Event Volatility Risk

Options market prices a ±6.9% implied move with a 0.56 put/call ratio around $41.00 max pain.

IMPL MOVE: ±6.9% // P/C: 0.56

03. Competitive Margin & CapEx Cycle Pressure

Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 8.2% net margins.

NET MARGIN: 8.2% // D/E: 1.74x

KEY CATALYST // Upcoming 10-Q/10-K XBRL margin progression, guidance revision vs 31.9x forward consensus, and institutional 13F positioning.

MACRO REGIME // Monitor US 10Y Real Yields (DFII10) and High-Yield Credit Spreads (OAS) for beta-adjusted multiple impact (Beta 1.00).

FORM 4 & 13F FLOW OPEN OWN <GO>

FILER	SIDE	$ VALUE
INSPECT FULL OWNERSHIP LEDGER IN OWN <GO>

UNUSUAL OPTIONS TAPE OPEN OPT <GO>

STRIKE / EXP	TYPE	PREMIUM
INSPECT GEX & CHAIN IN OPT <GO>

KEY VALUATION & PROFITABILITY RATIOS XBRL FA <GO>

TRAILING P/E 34.3x

FORWARD P/E 31.9x

EV / EBITDA 20.8x

FCF YIELD 1.81%

GROSS MARGIN 51.8%

OPERATING MARGIN 12.5%

NET MARGIN 8.2%

ROIC % 9.4%

REV GROWTH YOY +4.3%

DILUTED EPS TTM $1.21

DEBT / EQUITY 1.74x

DIVIDEND YIELD 0.00%

RSI-14 MOMENTUM 63.7

5Y EQUITY BETA 1.00

FRED MACRO SENSITIVITY (PEARSON r) ECST <GO>

MACRO CORRELATION CALIBRATION ACTIVE BELOW.

FRED MACRO REGIME STRESS-TEST SIMULATOR // TEVAPEARSON R VARIANCE ENGINE

01 // SELECT FEDERAL RESERVE & CREDIT SHOCK SCENARIO

02 // POSITION NOTIONAL EXPOSURE

HEADLINE STRESS SCORE

75/100SEVERE DRAWDOWN PRESSURE

PRIMARY FACTOR EXPOSURE

DFII10 // -0.61 r

Latest: 2.08%

EST. DIRECTIONAL MOVE

-8.50%

Implied Px: $37.95

EST. DOLLAR VARIANCE

-$4,248

On $50,000 Notional

[LOCKED // MULTI-FACTOR DRAWDOWN HEDGE & MACRO TRIGGER ALERT]

Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for TEVA & activate live FRED threshold breach alerts.

HEAD-TO-HEAD PEER COMPARISONS COMP <GO>

TEVA VS LLY

MARGINS ROIC VALUATION

TEVA VS JNJ

MARGINS ROIC VALUATION

TEVA VS ABBV

MARGINS ROIC VALUATION

TEVA VS UNH

MARGINS ROIC VALUATION